Brequinar is an orally available, small molecule, host-acting antiviral that inhibits the host enzyme dihydroorotate dehydrogenase (DHODH) to block de novo pyrimidine biosynthesis, potentially inhibiting SARS-CoV-2 replication.
Apr 28 2021 |
et al., NCT04575038 | The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2 |
| 205% higher hospitalization (p=0.49) and 34% worse viral clearance. RCT 115 outpatients in the USA, showing no significant differences with brequinar treatment. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.